The funding will help Castor EDC to roll out its direct-to-patient clinical trials services globally. Here are the top-line bullets you need to know.
Castor EDC, a clinical trial company, has raised $45M in Series B. The round drew participation from Eight Roads Ventures, INKEF Capital, F-Prime Capital, and Two Sigma Ventures.
HOW’S THE COMPANY PERFORMING?
- New Jersey-based Castor EDC is an AI-driven company for decentralized and hybrid clinical trials. The platform enables researchers to design studies and integrate data from any source in real-time. Additionally, patients can enroll and share data online via a mobile application.
- The company claims to have tripled its revenue in 2020 and is expected to achieve similar growth in 2021.
- Castor has reportedly doubled its size in the past 12 months, supporting over 7,500 studies across 90+ countries. It caters to major pharmaceutical companies including Stryker, Click Therapeutics, and Bloomlife, among others. Moreover, the World Health Organization hired the company for its Solidarity Trial.
- The company currently employs 150 people across offices in Hoboken, New York, and Amsterdam.
Source: Castor
WHY DOES THE MARKET MATTER?
- The global clinical trials market is projected to grow at a CAGR of 5.7% and reach a value of $69.5B by 2028, according to Grand View Research.
- The use of AI in healthcare has shown increasing potential in saving time by bringing drugs to markets faster through accurate patient identification for clinical trials.
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
